Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

ClinicalTrials.gov ID: NCT01708629

Public ClinicalTrials.gov record NCT01708629. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis. A second purpose of this study is to assess the safety and efficacy brodalumab at two different doses compared with ustekinumab in participants with moderate to severe plaque psoriasis. A third purpose of this study is to assess the safety and efficacy of 4 maintenance regimens of brodalumab.

Study identification

NCT ID
NCT01708629
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bausch Health Americas, Inc.
Industry
Enrollment
1,881 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2012
Primary completion
Jul 31, 2014
Completion
Sep 30, 2015
Last update posted
Jan 2, 2020

2012 – 2015

United States locations

U.S. sites
74
U.S. states
29
U.S. cities
69
Facility City State ZIP Site status
Research Site Birmingham Alabama 35205
Research Site Mobile Alabama 36608
Research Site Phoenix Arizona 85023
Research Site Beverly Hills California 90212
Research Site Burbank California 91505
Research Site Encino California 91436
Research Site Fremont California 94538
Research Site Fullerton California 92835
Research Site Irvine California 92614
Research Site Los Angeles California 90036
Research Site Riverside California 92505
Research Site Sacramento California 95819
Research Site San Diego California 92103
Research Site San Diego California 92123
Research Site San Francisco California 94118
Research Site Denver Colorado 80220
Research Site Farmington Connecticut 06030
Research Site Trumbull Connecticut 06611
Research Site Boca Raton Florida 33486
Research Site Coral Gables Florida 33134
Research Site Hollywood Florida 33021
Research Site Jacksonville Florida 32204
Research Site Miami Florida 33144
Research Site Ocala Florida 34471
Research Site Tamarac Florida 33321
Research Site Alpharetta Georgia 30022
Research Site Atlanta Georgia 30327
Research Site Macon Georgia 31217
Research Site Boise Idaho 83704
Research Site Arlington Heights Illinois 60005
Research Site Champaign Illinois 61820
Research Site Maywood Illinois 60153
Research Site Normal Illinois 61761
Research Site Wheaton Illinois 60189
Research Site Indianapolis Indiana 46256
Research Site New Albany Indiana 47150
Research Site Overland Park Kansas 66202
Research Site Overland Park Kansas 66215
Research Site Louisville Kentucky 40217
Research Site Owensboro Kentucky 42303
Research Site Worcester Massachusetts 01605
Research Site Ann Arbor Michigan 48103
Research Site Clarkston Michigan 48346
Research Site Clinton Township Michigan 48038
Research Site Henderson Nevada 89074
Research Site Las Vegas Nevada 89144
Research Site East Windsor New Jersey 08520
Research Site Hoboken New Jersey 07030
Research Site Verona New Jersey 07044
Research Site New York New York 10016
Research Site Rochester New York 14623
Research Site The Bronx New York 10467
Research Site High Point North Carolina 27262
Research Site Cincinnati Ohio 45249
Research Site Cleveland Ohio 44106
Research Site Lake Oswego Oregon 97035
Research Site Portland Oregon 97210
Research Site Exton Pennsylvania 19341
Research Site Johnston Rhode Island 02919
Research Site Greer South Carolina 29650
Research Site Bartlett Tennessee 38134
Research Site Nashville Tennessee 37205
Research Site Bellaire Texas 77401
Research Site Dallas Texas 75230
Research Site Dallas Texas 75231
Research Site Houston Texas 77004
Research Site Houston Texas 77030
Research Site Houston Texas 77082
Research Site Webster Texas 77598
Research Site Salt Lake City Utah 84132
Research Site Norfolk Virginia 23507
Research Site Richmond Virginia 23294
Research Site Spokane Washington 99204
Research Site Clarksburg West Virginia 26301

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 83 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01708629, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 2, 2020 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01708629 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →